Trial Profile
A randomized, double-blind, placebo-controlled, four-way crossover study of intranasal midazolam in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2016
Price :
$35
*
At a glance
- Drugs Midazolam (Primary)
- Indications Epilepsy; Sedation
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 21 Nov 2016 New trial record
- 25 Oct 2016 Results published in the British Journal of Clinical Pharmacology